Bioelectronics Corp (BIEL)

[bankrupt_2009]

UK here are Andy's answers to your questions along with one of mine:

1)How will you be exploiting this and what it means to the business?

The NHS approval for payment coverage only applies to the UK. We are seeking a marketing partner who calls on primary care and pain specialists and developing a marketing pain in the event we do not find a good marketing partner. The economics studies we did is good evidence to support getting reimbursement approvals in other markets and for US Health Maintenance Organizations, the VA, and other managed care grou

2) How many more pharmacies will be required to stock the product compared to the many chain pharmacies that already do.



In the UK patients need to get a prescription. The high volume pharmacies will stock the product. All pharmacies will be able to get same or next day delivery.


3) When will prescriptions be able to be written? (seems some confusion on this only the company can clear it up)

ActiPatch will be listed on the next Drug Tariff published in April. The Drug Tariff is the NHS list of medical products approved for payment. The pharmacist cannot process the prescriptions until the product is listed.


4) What is the communication/education plan to ensure that doctors (General practitioners especially) are given all the material they need to be convinced this is the first treatment option for chronic pain and also material for their patients to make them comfortable.



Please our answer to question number 1.



5) Is B Braun now putting ActiPatch/RecoveryRx inside post operation packs for hospital treatments such as knee and hip replacements?



Braun originally approached the NHS to determine if our RecoveryRx product could be reimbursed. We decided it would be better and easier to get the ActiPatch product cleared. We are waiting to see if we can get a marketing partner before we go back to Braun. Braun in the UK only markets and sells to orthopedic specialists.


6) Does / will the NHS make an announcement - the new media will more likely pick it up if it comes from them.



The NHS will work with industry on specific cost reduction strategies, which is why we prefer to partner with a UK pharmaceutical marketer.


7) Is anything similar being explored with Health Canada?


We have applications in Canada and Sweden, and will file additional applications as we proceed forward.